Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study

Table 2 Incidence rates, IR (per 1 person-year), incidence rates ratios, IRR, of reasons of treatment modifications the first year after initiation of HAART according to gender

	Toxicity IR (95% CI)	Other/UnknownIR (95% CI)	Toxicity IRR (95% CI)	Other/UnknownIRR (95% CI)
Adjusted for all listed confounders,
Men	0.52 (0.42-0.64)	0.55 (0.44-0.68)	1.00	1.00
Women	0.49 (0.41-0.59)	0.57 (0.48-0.67)	0.97 (0.66-1.44)	1.18 (0.76-1.85)
Women (pregnant excluded)	0.54 (0.45-0.66)	0.49 (0.40-0.61)	1.03 (0.69-1.52)	1.14 (0.71-1.82)

Poisson regression analyses of incidence rates, IR (95% CI), and incidence rates ratios, IRR (95% CI), adjusted by time-updated age, race, time-updated CD4 count, time-updated viral load, prior or current AIDS at HAART initiation, body weight and initiation period (< January 1^st 2003 and >= January 1^st 2003).

ISSN: 1471-2334